Assay concordance between SPA and TR-FRET in high-throughput screening

被引:27
作者
von Ahsen, Oliver [1 ]
Schmidt, Anne [1 ]
Klotz, Monika [1 ]
Parczyk, Karsten [1 ]
机构
[1] Schering AG, Enabling Technol, Dept Assay Dev & High Throughput Screening, D-13342 Berlin, Germany
关键词
assay techniques; tyrosine kinase; high-throughput screening; TR-FRET; SPA; assay concordance;
D O I
10.1177/1087057106288183
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
High-throughput screening (HTS) of large chemical libraries has become the main source of new lead compounds for drug development. Several specialized detection technologies have been developed to facilitate the cost- and time-efficient screening of millions of compounds. However, concerns have been raised, claiming that different HTS technologies may produce different hits, thus limiting trust in the reliability of HTS data. This study was aimed to investigate the reliability of the authors most frequently used assay techniques: scintillation proximity assay (SPA) and homogeneous time-resolved fluorescence resonance energy transfer (TR-FRET). To investigate the data concordance between these 2 detection technologies, the authors screened a large subset of the Schering compound library consisting of 300,000 compounds for inhibitors of a nonreceptor tyrosine kinase. They chose to set up this study in realistic HTS scale to ensure statistical significance of the results. The findings clearly demonstrate that the choice of detection technology has no significant impact on hit finding, provided that assays are biochemically equivalent. Data concordance is up to 90%. The little differences in hit findings are caused by threshold setting but not by systematic differences between the technologies. The most significant difference between the compared techniques is that in the SPA format, more false-positive primary hits were obtained.
引用
收藏
页码:606 / 616
页数:11
相关论文
共 20 条
[1]  
Chan James A, 2002, Methods Mol Biol, V190, P117
[2]   Mechanistic considerations in high-throughput screening [J].
Copeland, RA .
ANALYTICAL BIOCHEMISTRY, 2003, 320 (01) :1-12
[3]  
Devlin JJ, 1996, DRUG DEVELOP RES, V37, P80, DOI 10.1002/(SICI)1098-2299(199602)37:2<80::AID-DDR3>3.0.CO
[4]  
2-H
[5]   Statistical evaluation of a self-deconvoluting matrix strategy for high-throughput screening of the CXCR3 receptor [J].
Ferrand, S ;
Schmid, A ;
Engeloch, C ;
Glickman, JF .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2005, 3 (04) :413-424
[6]   Novel detection strategies for drug discovery [J].
Hemmilä, IA ;
Hurskainen, P .
DRUG DISCOVERY TODAY, 2002, 7 (18) :S150-S156
[7]   High-throughput screening: new technology for the 21st century [J].
Hertzberg, RP ;
Pope, AJ .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2000, 4 (04) :445-451
[8]   Data concordance from a comparison between filter binding and fluorescence polarization assay formats for identification of ROCK-II inhibitors [J].
Hubert, CL ;
Sherling, SE ;
Johnston, PA ;
Stancato, LF .
JOURNAL OF BIOMOLECULAR SCREENING, 2003, 8 (04) :399-409
[9]   Managing the drug discovery/development interface [J].
Kennedy, T .
DRUG DISCOVERY TODAY, 1997, 2 (10) :436-444
[10]   How many leads from HTS? [J].
Lahana, R .
DRUG DISCOVERY TODAY, 1999, 4 (10) :447-448